Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: Long-term results of a phase II study

Journal of Clinical Oncology

Volumn 23, Issue 6, 2005, Pages 1144-1151

  Jeremic, Branislav ^a   Milicic, Biljana ^a   Acimovic, Ljubisa ^a   Milisavljevic, Slobodan ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGUS DISEASE; FEMALE; HUMAN; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; FOLLOW UP; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; SURVIVAL RATE;

EID: 14544305080     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.015     Document Type: Article

References (59)

1. Choi NC, Doucette JA: Improved survival of patients with unresectable non-small cell bronchogenic carcinoma by an innovated high-dose en bloc radiotherapeutic approach. Cancer 48:101-109, 1981
2. Perez C, Stanley K, Grundy G, et al: Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Cancer 50:1091-1099, 1982
3. Petrovich Z, Stanley K, Cox J, et al: Radiotherapy and the management of locally advanced lung cancer of all cell types: Final report of randomized trial. Cancer 48:1335-1340, 1981
4. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996
5. LeChevalier T, Arriagada R, Lacombe-Terrier M-J, et al: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. J Natl Cancer Inst 84:58, 1992
6. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588: Preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
7. Sause WT, Kolesar P, Taylor S IV, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117:358-364, 2000
8. Byhardt RW, Scott CB, Ettinger DS, et al: Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer: Results of Radiation Therapy Oncology Group 90-15. Cancer 75:2337-2344, 1995
9. Komaki R, Scott C, Ettinger D, et al: Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 38:149-155, 1997
10. Lau DH, Ryu JK, Gandara DR, et al: Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: A pilot study. Int J Radiat Oncol Biol Phys 38:157-161, 1997
11. Lee JS, Scott C, Komaki R, et al: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 14:1055-1064, 1996
12. Jeremic B, Shibamoto Y, Acimovic Lj, et al: Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995
13. Jeremic B, Shibamoto Y, Acimovic Lj, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996
14. Schaake-Konig C, van der Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524-530, 1992
15. Furuse K, Nishikawa H, Takada Y, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999
16. Furuse K, Hosoe S, Masuda N: Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT) and chemotherapy (CT). Proc Am Soc Clin Oncol 19:484a, 2000 (abstr 1893)
17. Curran WJ Jr, Scott C, Langer C: Phase III comparison of sequential Vs concurrent chemoradiation for pts with unresected stage III nonsmall cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 19:484a, 2000 (abstr 1891)
18. Komaki R, Seiferheld W, Curran W, et al: Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410). Proc Am Soc Ther Radiol Oncol 42:113, 2000 (abstr 5)
19. Jeremic B, Shibamoto Y, Milicic B, et al: Concurrent radiochemotherapy for patients with stage III non-small cell lung cancer (NSCLC): Long-term results of a phase 11 study. Int J Radiat Oncol Biol Phys 42:1091-1096, 1998
20. Jeremic B, Shibamoto Y, Acimovic LJ, et al: Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: A randomized trial. Int J Radiat Oncol Biol Phys 50:19-25, 2001
21. Chang AY, Kim K, Click J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993
22. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
23. Hainsworth JD, Thompson DS, Greco FA: Paclitaxel by 1-hour infusion: An active drug in metastatic non-small cell lung cancer. J Clin Oncol 13:1609-1614, 1995
24. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995
25. Choy H, Rodriguez F, Koester S, et al: Investigation of Taxol as a potential radiosensitizer. Cancer 71:3774-3778, 1993
26. Geard CR, Jones JM, Schiff PB: Taxol and radiation. J Natl Cancer Inst Monogr 15:89-94, 1993
27. Tishler R, Schiff PB, Geard C, et al: Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617, 1992
28. Liebman J, Cook J, Fisher J, et al: In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86:441-446, 1994
29. Mlinarik L, Hall EJ: Taxol in combination with acute and low-dose rate irradiation. Radiother Oncol 32:124-128, 1994
30. Milas L, Hunter N, Mason K, et al: Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54:3506-3510, 1994
31. Bunn PA Jr, Kelly K: A phase I study of carboplatin and paclitaxel in non-small-cell lung cancer: A University of Colorado Cancer Center study. Semin Oncol 22:2-6, 1995 (suppl 9)
32. Mountain CF: A new international staging system for lung cancer. Chest 89:2255-2335, 1986 (suppl 1)
33. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Treatment and Research of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995
34. Tishler RB, Geard CR, Hall EJ, et al: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495-3497, 1992
35. National Cancer Institute: Taxol clinical brochure. Bethesda, MD, National Cancer Institute, NIH publication 125973, 1991
36. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
37. Albain KS, Crowley JJ, Turrisi AT III, et al: Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II study, SWOG 9019. J Clin Oncol 20:3454-3460, 2002
38. Gandara DR, Chansky K, Albain KS, et al: Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010, 2003
39. Choy H, Browne MJ: Paclitaxel as a radiation sensitizer in non-small-cell lung cancer. J Clin Oncol 12:2682-2686, 1994
40. Vogt HG, Kolotas C, Martin T, et al: Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: A clinical phase I study. Semin Oncol 23:120-123, 1996
41. Kirkbride P, Gelmon K, Eisenhauer E, et al: A phase I/II study of paclitaxel (Taxol) and concurrent radiotherapy in advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 39:1107-1111, 1997
42. Herscher LL, Hahn SM, Kroog G, et al: Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol 16:635-641, 1998
43. Dowell JE, Sinard R, Yardley DA, et al: Seven-week continuous-infusion paclitaxel for locally advanced non-small cell lung cancer and head and neck cancers. Semin Radiat Oncol 9:97-101, 1999
44. Lau D, Leigh B, Gandara D, et al: Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/ paclitaxel consolidation for stage III non-small-cell lung cancer: A California Cancer Consortium phase II trial. J Clin Oncol 19:442-447, 2001
45. Chen Y, Pandya K, Keng PC, et al: Phase I/II clinical study of pulsed paclitaxel radiosensitization of thoracic malignancy: A therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin Cancer Res 9:969-975, 2003
46. Choy H, Safran H, Akerley W, et al: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4:1931-1936, 1998
47. Choy H, Akerley W, Safran H, et al: Multi-institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16:3316-3322, 1998
48. Wolf M, Faoro C, Goerg C, et al: Paclitaxel and simultaneous radiation in the treatment of stage IIIA/B non-small cell lung cancer. Semin Oncol 23:108-112, 1996
49. Choy H, Devore RF III, Hande KR, et al: A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer: A Vanderbilt cancer Center affiliate network study. Int J Radiat Oncol Biol Phys 47:931-937, 2000
50. Ratanatharathorn V, Lorvidhaya V, Maoleekoonpairoj S, et al: Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Lung Cancer 31:257-265, 2001
51. Zajda K, Wierschowski M, Lasota W, et al: Preliminary results of phase II study of paclitaxel administered daily plus carboplatin with concurrent chest radiation followed by consolidation chemotherapy with paclitaxel and carboplatin in locally advanced NSCLC. Proc Am Soc Clin Oncol 22:275, 2003 (abstr 2811)
52. Choy H, Curran WJ, Scott CB, et al: Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427-A randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol 21:291 a, 2002 (abstr 1160)
53. Ulutin HC, Pak Y: Preliminary results of radiotherapy with or without weekly paclitaxel in locally advanced non-small cell lung cancer. J Cancer Res Clin Oncol 129:52-56, 2003
54. Marangolo M, Emiliani E, Rosi G, et al: Paclitaxel and radiotherapy in the treatment of advanced non-small cell lung cancer. Semin Oncol 23:31-34, 1996 (suppl 15)
55. Reckzeh B, Merte H, Pfluger K-H, et al: Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 14:1071-1076, 1996
56. Belani CP, Aisner J, Bahri S, et al: Chemoradiotherapy in non-small cell lung cancer: Paclitaxel/carboplatin/radiotherapy in regionally advanced disease. Semin Oncol 23:113-116, 1996 (suppl 16)
57. Graham MV, Purdy JA, Emami B, et al: Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 33:993-1000, 1995
58. Robertson JM, Ten Haken RK, Hazuka MB, et al: Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 37:1079-1085, 1997
59. Zanelli GD, Quaia M, Robieux I, et al: Paclitaxel as a radiosensitizer: A proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 33:486-492, 1997